Skip to main content

NASDAQ:JUNO - 1877 Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$86.96
+0.30 (1.20%)
Get New 1877 Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JUNO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JUNO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for 1877 in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $86.96.

N/A

The current consensus among 0 polled investment analysts is to n/a stock in 1877. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2018Standpoint ResearchReiterated RatingBuy ➝ HoldLow
i
1/24/2018BarclaysDowngradeOverweight ➝ Equal Weight$55.00 ➝ $87.00Low
i
1/23/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$56.00 ➝ $87.00Low
i
1/23/2018Raymond JamesDowngradeOutperform ➝ HoldLow
i
Rating by Reni Benjamin at Raymond James
1/22/2018SunTrust BanksReiterated RatingBuy ➝ HoldLow
i
1/22/2018Needham & Company LLCDowngradeBuy ➝ HoldLow
i
1/22/2018GuggenheimDowngradeBuy ➝ NeutralLow
i
1/17/2018Raymond JamesReiterated RatingOutperform ➝ BuyHigh
i
Rating by Reni Benjamin at Raymond James
1/17/2018CitigroupDowngradeBuy ➝ NeutralHigh
i
1/17/2018WedbushDowngradeOutperform ➝ NeutralHigh
i
Rating by D. Nierengarten at Wedbush
1/17/2018Wells Fargo & CompanyReiterated RatingMarket Perform$54.00 ➝ $63.00High
i
1/11/2018Raymond JamesReiterated RatingBuyMedium
i
Rating by Reni Benjamin at Raymond James
1/11/2018JPMorgan Chase & Co.Reiterated RatingHoldHigh
i
1/5/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$65.00Medium
i
12/13/2017Maxim GroupSet Price TargetBuy$56.00High
i
Rating by Jason McCarthy at Maxim Group
12/12/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformHigh
i
12/11/2017Raymond JamesReiterated RatingBuyHigh
i
Rating by Reni Benjamin at Raymond James
11/3/2017Raymond JamesBoost Price TargetOutperform$45.00 ➝ $61.00N/A
i
Rating by Reni Benjamin at Raymond James
11/3/2017CowenReiterated RatingBuyN/A
i
11/2/2017Maxim GroupReiterated RatingBuy$56.00N/A
i
11/2/2017SVB LeerinkReiterated RatingOutperform ➝ In-Line$34.00 ➝ $56.00N/A
i
11/2/2017WedbushReiterated RatingOutperform$42.00 ➝ $64.00N/A
i
Rating by D. Nierengarten at Wedbush
11/2/2017SunTrust BanksUpgradeHold ➝ BuyN/A
i
10/31/2017CitigroupReiterated RatingBuy$59.00N/A
i
10/27/2017CowenReiterated RatingBuy$49.00N/A
i
10/9/2017Maxim GroupReiterated RatingBuy ➝ Buy$34.00 ➝ $56.00N/A
i
10/6/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$44.00N/A
i
10/6/2017Morgan StanleyReiterated RatingEqual Weight$27.00 ➝ $43.00N/A
i
9/6/2017BarclaysInitiated CoverageOverweight$55.00Medium
i
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$35.00 ➝ $54.00Low
i
8/31/2017Standpoint ResearchReiterated RatingBuy ➝ ReduceMedium
i
8/29/2017Raymond JamesUpgradeMarket Perform ➝ Outperform$45.00High
i
Rating by Reni Benjamin at Raymond James
8/29/2017WedbushUpgradeNeutral ➝ Outperform$42.00 ➝ $42.00High
i
Rating by D. Nierengarten at Wedbush
8/28/2017BTIG ResearchUpgradeSell ➝ NeutralHigh
i
8/7/2017Morgan StanleyBoost Price TargetEqual ➝ Equal Weight$26.00 ➝ $27.00Low
i
6/20/2017SVB LeerinkReiterated RatingOutperform$34.00Low
i
6/12/2017SVB LeerinkReiterated RatingOutperformLow
i
6/8/2017BTIG ResearchDowngradeNeutral ➝ Sell$22.60 ➝ $23.73Low
i
6/6/2017WedbushReiterated RatingNeutral$24.00Medium
i
6/6/2017BTIG ResearchDowngradeNeutral ➝ Sell$12.00 ➝ $23.00Medium
i
5/18/2017(FBRC)Reiterated RatingHoldMedium
i
Rating by Edward White at (FBRC)
5/15/2017WedbushReiterated RatingNeutral$24.00N/A
i
5/8/2017Morgan StanleyLower Price TargetEqual Weight$27.00 ➝ $26.00High
i
5/5/2017WedbushReiterated RatingNeutral$24.00High
i
5/5/2017(FBRC)Lower Price TargetMkt Perform ➝ Mkt Perform$30.00 ➝ $29.00High
i
Rating by Edward White at (FBRC)
4/4/2017CitigroupLower Price TargetBuy$34.00 ➝ $30.00Low
i
3/30/2017CowenReiterated RatingBuy$41.00 ➝ $36.00Low
i
3/3/2017JPMorgan Chase & Co.Reiterated RatingNeutral$34.00 ➝ $31.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
3/3/2017WedbushReiterated RatingNeutral$24.00N/A
i
3/2/2017(FBRC)Set Price TargetHold$30.00N/A
i
Rating by Edward White at (FBRC)
3/2/2017Maxim GroupSet Price TargetBuy$34.00N/A
i
Rating by Jason McCarthy at Maxim Group
2/22/2017Wells Fargo & CompanyInitiated CoverageOutperform ➝ OutperformN/A
i
2/1/2017WedbushInitiated CoverageNeutral$24.00N/A
i
1/11/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/6/2016(FBRC)Set Price TargetHold$30.00N/A
i
Rating by Edward White at (FBRC)
12/6/2016Raymond JamesReiterated RatingOutperform ➝ Market PerformN/A
i
12/5/2016CowenReiterated RatingBuy$51.00N/A
i
Rating by Chris Shibutani at Cowen Inc
12/5/2016Maxim GroupSet Price TargetBuy$34.00N/A
i
Rating by Jason McCarthy at Maxim Group
12/1/2016JPMorgan Chase & Co.Reiterated RatingHold$34.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/28/2016SVB LeerinkReiterated RatingOutperform$45.00 ➝ $34.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
11/25/2016SunTrust BanksDowngradeBuy ➝ Hold$48.00 ➝ $25.00N/A
i
11/24/2016JPMorgan Chase & Co.Set Price TargetHold$39.00 ➝ $34.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/23/2016BTIG ResearchReiterated RatingNeutralN/A
i
11/23/2016Maxim GroupLower Price TargetBuy$50.00 ➝ $34.00N/A
i
11/23/2016(FBRC)DowngradeOutperform ➝ Market Perform$30.00N/A
i
Rating by Edward White at (FBRC)
11/3/2016BTIG ResearchUpgradeSell ➝ NeutralN/A
i
10/15/2016(FBRC)Reiterated RatingOutperform$61.00N/A
i
Rating by Edward White at (FBRC)
9/27/2016SVB LeerinkReiterated RatingOutperform$45.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
9/9/2016BTIG ResearchReiterated RatingSell$23.00N/A
i
8/30/2016BTIG ResearchInitiated CoverageSell$23.00N/A
i
8/25/2016Standpoint ResearchInitiated CoverageBuy$47.00N/A
i
8/5/2016(FBRC)Set Price TargetBuy$61.00N/A
i
Rating by Edward White at (FBRC)
8/5/2016Maxim GroupLower Price TargetBuy$80.00 ➝ $50.00N/A
i
Rating by Jason McCarthy at Maxim Group
7/18/2016Maxim GroupReiterated RatingBuy$80.00N/A
i
Rating by Jason McCarthy at Maxim Group
7/14/2016SVB LeerinkReiterated RatingBuy$86.00N/A
i
7/10/2016Maxim GroupReiterated RatingBuy$80.00N/A
i
Rating by Jason McCarthy at Maxim Group
7/10/2016CowenReiterated RatingBuy$55.00N/A
i
7/9/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Edward White at (FBRC)
7/8/2016SVB LeerinkReiterated RatingOutperform$60.00N/A
i
7/8/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$63.00 ➝ $39.00N/A
i
7/8/2016(FBRC)Lower Price TargetOutperform$73.00 ➝ $61.00N/A
i
Rating by Edward White at (FBRC)
7/6/2016BarclaysInitiated CoverageEqual Weight$48.00N/A
i
6/6/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Edward White at (FBRC)
6/2/2016Raymond JamesInitiated CoverageOutperform$52.00N/A
i
(Data available from 5/16/2016 forward)
1877 logo
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.
Read More

Today's Range

Now: $86.96
$86.96
$86.96

50 Day Range

MA: $86.96
$86.96
$86.96

52 Week Range

Now: $86.96
$19.62
$87.01

Volume

2 shs

Average Volume

5,484,542 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of 1877?

The following equities research analysts have issued stock ratings on 1877 in the last twelve months:
View the latest analyst ratings for JUNO.

What is the current price target for 1877?

0 Wall Street analysts have set twelve-month price targets for 1877 in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for 1877 in the next year.
View the latest price targets for JUNO.

What is the current consensus analyst rating for 1877?

1877 currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for JUNO.

How do I contact 1877's investor relations team?

1877's physical mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States. The biopharmaceutical company's listed phone number is +1-206-5821600. The official website for 1877 is www.junotherapeutics.com.